{"id":967,"date":"2019-12-04T17:33:02","date_gmt":"2019-12-04T16:33:02","guid":{"rendered":"https:\/\/dose-innova.ccoo.cat\/?p=967"},"modified":"2019-12-04T17:33:02","modified_gmt":"2019-12-04T16:33:02","slug":"estructura-salarial-2","status":"publish","type":"post","link":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/estructura-salarial-2\/","title":{"rendered":"Estructura Salarial"},"content":{"rendered":"\n<p><span style=\"font-size: 14pt\"><strong>Estructura salarial<\/strong><\/span><\/p>\n\n\n\n<p>L&#8217;estructura salarial en&nbsp;Dose&nbsp;Innova es compon de:&nbsp;SMG&nbsp;+ PC + CP.<\/p>\n\n\n\n<p><strong>1.&nbsp;SMG:<\/strong> \u00c9s el <strong>Salari M\u00ednim Garantit<\/strong> pel Conveni General de les Ind\u00fastries Qu\u00edmiques per a cada grup professional, d&#8217;obligat compliment per a totes les empreses.<\/p>\n\n\n\n<p><strong>2. PC:<\/strong> <strong>Plus Conveni<\/strong>. En&nbsp;Dose&nbsp;Innova es defineix com el 35% del&nbsp;SMG.<\/p>\n\n\n\n<p><strong>3. CP:<\/strong> <strong>Complement personal<\/strong>. Est\u00e0 format per tot el salari que no correspongui als conceptes Salari M\u00ednim Garantit, Plus Conveni, plus d&#8217;antiguitat, treball per torns, nocturnitat, perillositat , toxicitat i complement de lloc de treball. En Dose Innova totes les treballadores i treballadors han de tenir, per acord col\u00b7lectiu, un Complement Personal m\u00ednim del 3% corresponent a la suma de SMG i PC.<\/p>\n\n\n\n<p>Les quantitats abans indicades s&#8217;abonen en 14 pagues i es resumeixen en:<\/p>\n\n\n\n<hr class=\"wp-block-separator\" \/>\n\n\n\n<p><strong><span style=\"color: #800000\">Grupo 1<\/span><\/strong><\/p>\n\n\n\n<p><strong>SMG:<\/strong> 15.264,57 \u20ac<\/p>\n\n\n\n<p><strong>Plus CGIQ:<\/strong> 5.342,60 \u20ac<\/p>\n\n\n\n<p><strong>CP:<\/strong> 618,22 \u20ac<\/p>\n\n\n\n<p><strong>Total:<\/strong> 21.225,37 \u20ac<\/p>\n\n\n\n<hr class=\"wp-block-separator\" \/>\n\n\n\n<p><strong><span style=\"color: #800000\">Grupo 2<\/span><\/strong><\/p>\n\n\n\n<p><strong>SMG<\/strong>: 16.333,08&nbsp;\u20ac<\/p>\n\n\n\n<p><strong>Plus CGIQ<\/strong>: 5.716,58 \u20ac<\/p>\n\n\n\n<p><strong>CP<\/strong>: 661,49 \u20ac<\/p>\n\n\n\n<p><strong>Total<\/strong>: 22.711,15 \u20ac<\/p>\n\n\n\n<hr class=\"wp-block-separator\" \/>\n\n\n\n<p><strong><span style=\"color: #800000\">Grupo 3<\/span><\/strong><\/p>\n\n\n\n<p><strong>SMG<\/strong>: 17.706,92 \u20ac<\/p>\n\n\n\n<p><strong>Plus CGIQ<\/strong>: 6.197,42 \u20ac<\/p>\n\n\n\n<p><strong>CP<\/strong>: 717,13 \u20ac<\/p>\n\n\n\n<p><strong>Total<\/strong>: 24.621,46 \u20ac<\/p>\n\n\n\n<hr class=\"wp-block-separator\" \/>\n\n\n\n<p><strong><span style=\"color: #800000\">Grupo 4<\/span><\/strong><\/p>\n\n\n\n<p><strong>SMG<\/strong>: 19.211,04 \u20ac<\/p>\n\n\n\n<p><strong>Plus CGIQ<\/strong>: 6.891,96 \u20ac<\/p>\n\n\n\n<p><strong>CP<\/strong>: 797,50 \u20ac<\/p>\n\n\n\n<p><strong>Total<\/strong>: 27.380,77 \u20ac<\/p>\n\n\n\n<hr class=\"wp-block-separator\" \/>\n\n\n\n<p><strong><span style=\"color: #800000\">Grupo 5<\/span><\/strong><\/p>\n\n\n\n<p><strong>SMG<\/strong>: 22.438,25 \u20ac<\/p>\n\n\n\n<p><strong>Plus CGIQ<\/strong>: 7.853,39 \u20ac<\/p>\n\n\n\n<p><strong>CP<\/strong>: 908,74 \u20ac<\/p>\n\n\n\n<p><strong>Total<\/strong>: 31.200,39 \u20ac<\/p>\n\n\n\n<hr class=\"wp-block-separator\" \/>\n\n\n\n<p><strong><span style=\"color: #800000\">Grupo 6<\/span><\/strong><\/p>\n\n\n\n<p><strong>SMG<\/strong>: 26.255,10 \u20ac<\/p>\n\n\n\n<p><strong>Plus CGIQ<\/strong>: 9.189,29 \u20ac<\/p>\n\n\n\n<p><strong>CP<\/strong>: 1.063,34 \u20ac<\/p>\n\n\n\n<p><strong>Total<\/strong>: 36.507,71 \u20ac<\/p>\n\n\n\n<hr class=\"wp-block-separator\" \/>\n\n\n\n<p><strong><span style=\"color: #800000\">Grupo 7<\/span><\/strong><\/p>\n\n\n\n<p><strong>SMG<\/strong>: 31.902,94 \u20ac<\/p>\n\n\n\n<p><strong>Plus CGIQ<\/strong>: 11.166,03 \u20ac<\/p>\n\n\n\n<p><strong>CP<\/strong>: 1.292,07 \u20ac<\/p>\n\n\n\n<p><strong>Total<\/strong>: 44.361,04 \u20ac<\/p>\n\n\n\n<hr class=\"wp-block-separator\" \/>\n\n\n\n<p><strong><span style=\"color: #800000\">Grupo 8<\/span><\/strong><\/p>\n\n\n\n<p><strong>SMG<\/strong>: 40.451,09 \u20ac<\/p>\n\n\n\n<p><strong>Plus CGIQ<\/strong>: 14.157,88 \u20ac<\/p>\n\n\n\n<p><strong>CP<\/strong>: 1.638,27 \u20ac<\/p>\n\n\n\n<p><strong>Total<\/strong>: 56.247,24 \u20ac<\/p>\n\n\n\n<hr class=\"wp-block-separator\" \/>\n\n\n\n<p>Els grups 1, 2, 3 i 4 tenen a m\u00e9s, una quantitat de 2.400\u20ac anuals afegida al Complement Personal (a partir dels 2 anys d&#8217;antiguitat)<\/p>\n\n\n\n<p><strong><span style=\"color: #800000\">Altres complements&nbsp;<\/span><\/strong><\/p>\n\n\n\n<p><span style=\"color: #000000\"><strong>Torn nit<\/strong><\/span>: 25% del SBM<br><strong>Torn tarda<sup>1<\/sup><\/strong>: 11,64 \u20ac<br><strong>Rotaci\u00f3<\/strong>: 7,72 \u20ac<br><strong>Dissabte 4\u00ba turno<\/strong>: 148,27 \u20ac<br><strong>Diumenge\/festiu 4\u00ba torn<\/strong>: 180,72 \u20ac<br><strong>Setmana Santa i Nadai <\/strong>: 89,29 \u20ac<br><strong>Fix torn mati (pagament \u00fanic)<\/strong>: 1005,51 \u20ac<br><strong>Cap de setmana i festius:<\/strong>&nbsp;97,73 \u20ac<br><strong>Complement back-up log\u00edstica:<\/strong>&nbsp;9,50 \u20ac<br><strong>Complement back-up lider l\u00ednia torn<\/strong>: 16,18 \u20ac<br><strong>Gu\u00e0rdia cap de setmana manteniment serveis generals:<\/strong>&nbsp;560 \u20ac<br><strong>Gu\u00e0rdia telef\u00f2nica<\/strong>: 100 \u20ac<br><b>Gu\u00e0rdia EBR &#8211; Inform\u00e1tica industrial<\/b>: 400 \u20ac<br><strong>Solape<\/strong>: 6,58 \u20ac<\/p>\n\n\n\n<p><sup>1<\/sup>Per als treballadors i treballadores afectats per l&#8217;acord de trasllat de 1989.<\/p>\n    \t","protected":false},"excerpt":{"rendered":"<p>Estructura salarial L&#8217;estructura salarial en&nbsp;Dose&nbsp;Innova es compon de:&nbsp;SMG&nbsp;+ PC + CP. 1.&nbsp;SMG: \u00c9s el Salari M\u00ednim Garantit pel Conveni General de les Ind\u00fastries Qu\u00edmiques per a cada grup professional, d&#8217;obligat &#8230; <a title=\"Estructura Salarial\" class=\"read-more\" href=\"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/estructura-salarial-2\/\" aria-label=\"Leer m\u00e1s sobre Estructura Salarial\">Leer m\u00e1s<\/a><\/p>\n","protected":false},"author":59,"featured_media":694,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-967","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-estructurasalarial_ca","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-33"],"_links":{"self":[{"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/posts\/967","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/users\/59"}],"replies":[{"embeddable":true,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/comments?post=967"}],"version-history":[{"count":0,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/posts\/967\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/media\/694"}],"wp:attachment":[{"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/media?parent=967"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/categories?post=967"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ccoo.app\/towa-pharmaceutical-europe\/wp-json\/wp\/v2\/tags?post=967"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}